Related Experiment Videos
Plasma fibronectin in hemoblastosis
G Curci1, A Frassoldati, F Zioni
1Cattedra di Terapia Medica Sistematica, University of Modena, Italy.
The International Journal of Biological Markers
|May 1, 1987
Summary
Plasma fibronectin (FN) levels in hemoblastosis patients showed a weak correlation with disease progression but responded dynamically to treatment, suggesting limited utility as a tumor marker.
Area of Science:
- Biochemistry and Molecular Biology
- Oncology
- Hematology
Background:
- Fibronectin (FN) is a crucial glycoprotein involved in various physiological processes.
- Reduced plasma FN concentrations are observed in numerous pathological conditions, including cancers.
- Hemoblastosis, a group of blood cancers, presents complex clinical and biological parameters.
Purpose of the Study:
- To evaluate the potential of plasma fibronectin as a tumor marker in hemoblastosis.
- To correlate plasma FN levels with clinical and biological parameters of hemoblastosis.
- To assess the dynamic behavior of fibronectin in relation to disease course and treatment.
Main Methods:
- Plasma fibronectin concentrations were measured in patients with hemoblastosis.
- FN levels were correlated with disease stage, hepatosplenomegaly, infections, and disseminated intravascular coagulation (DIC).
- The protein's behavior was monitored in response to therapeutic interventions.
Main Results:
- A poor correlation was observed between plasma FN levels and the overall course of hemoblastosis.
- Fibronectin levels did not consistently reflect disease progression or severity.
- However, FN levels exhibited dynamic changes in response to treatment regimens.
Conclusions:
- Plasma fibronectin is unlikely to be a reliable tumor marker for monitoring hemoblastosis progression.
- The dynamic changes in FN during treatment warrant further investigation.
- Further research is needed to elucidate the specific role of fibronectin in hemoblastosis pathophysiology and treatment response.